Antineoplastic combinations

Liposomal daunorubicin with cytarabine

(Danuorubicin 44mg / Cytarabine 100mg)

• Vyxeos liposomal powder for concentrate for solution for infusion vials 44mg/100mg

Notes

1. NICE TA552: Liposomal cytarabine–daunorubicin (Vyxeos) is recommended, within its marketing authorisation, as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults (December 2018)
   1. It is recommended only if the company provides it according to the commercial arrangement.
2. MHRA Drug Safety Update (July 2020): Liposomal and lipid-complex formulations: name change to reduce medication errors.

Trifluridine with tipiracil

• Tablets trifluridine 15mg/tipiracil 6.14mg, trifluridine 20mg/tipiracil 8.19mg

Notes

1. NICE TA405: Trifluridine–tipiracil (Lonsurf) is recommended as an option for treating metastatic colorectal cancer (August 2016), that is:
   1. in adults who have had previous treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable, and
   2. only when the company provides trifluridine–tipiracil with the discount agreed in the patient access scheme.
2. NICE TA852: Trifluridine–tipiracil (Lonsurf) is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimes, only if the company provides it according to the commercial arrangement (December 2022).
3. NICE TA1008: Trifluridine-tipiracil (Lonsurf) with bevacizumab is recommended, within its marketing authorisation, for treating metastatic colorectal cancer in adults who have had 2 lines of treatment (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, antivascular endothelial growth factor or anti-epidermal growth factor receptor treatments), only if the company provides trifluridine–tipiracil according to the commercial arrangement (September 2024).